• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Revvity Inc.

    4/25/25 4:06:40 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    8-K
    false 0000031791 --12-29 0000031791 2025-04-22 2025-04-22 0000031791 us-gaap:CommonStockMember 2025-04-22 2025-04-22 0000031791 us-gaap:DeferrableNotesMember 2025-04-22 2025-04-22
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): April 22, 2025

     

     

    Revvity, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Massachusetts   001-05075   04-2052042

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    77 4th Avenue, Waltham, Massachusetts   02451
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: (781) 663-6900

    Not applicable.

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

      ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

      ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol

     

    Name of exchange

    on which registered

    Common stock, $1 par value per share   RVTY   The New York Stock Exchange
    1.875% Notes due 2026   RVTY26   The New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.03

    Amendments to Articles of Organization or Bylaws; Change in Fiscal Year

    At the annual meeting of shareholders of Revvity, Inc. (the “Company”) held on April 22, 2025, the shareholders voted on and approved a proposal to amend the Company’s Restated Articles of Organization, as amended (the “Articles of Organization”), to implement a majority voting standard for specified corporate actions (the “Majority Voting Standard”). On April 23, 2025, the Company filed articles of amendment to the Articles of Organization (the “Articles of Amendment”) with the Secretary of the Commonwealth of Massachusetts (the “Secretary of the Commonwealth”) to effect the amendments to the Articles of Organization approved by the shareholders. Subsequently, on the same day, the Company filed articles of correction to the Articles of Organization (the “Articles of Correction”) with the Secretary of the Commonwealth to include a page of the Articles of Amendment that was included in the Company’s transmission of the Articles of Amendment to the Secretary of the Commonwealth but which was not received by the Secretary of the Commonwealth. Copies of the Articles of Amendment and the Articles of Correction, both effective as of April 23, 2025, are attached hereto as Exhibit 3.1 and Exhibit 3.2, respectively, and incorporated herein by reference.

    In connection with the Majority Voting Standard, the board of directors of the Company approved an amendment and restatement of the Company’s Amended and Restated By-laws (prior to such amendment and restatement, the “Prior By-laws”) to, among other updates, implement the Majority Voting Standard (as amended and restated, the “Amended and Restated By-laws”) effective as of April 24, 2025. A copy of the Amended and Restated By-laws, in redline form to show the amendments made by the Company to the Prior By-laws, is attached hereto as Exhibit 3.3 and incorporated herein by reference.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    At the annual meeting of shareholders of the Company held on April 22, 2025, the shareholders voted on the following proposals:

     

      •  

    a proposal to elect the ten nominees for director named below for terms of one year each;

     

      •  

    a proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the current fiscal year;

     

      •  

    a proposal to approve, by non-binding advisory vote, the Company’s executive compensation;

     

      •  

    a proposal to amend the Company’s Restated Articles of Organization, as amended, and the Company’s Amended and Restated By-laws to implement the Majority Voting Standard; and

     

      •  

    a shareholder proposal regarding ability to call special shareholder meeting.

    The shareholders elected each of the nominees to serve as a director for a term of one year. The final number of votes cast for or against or abstaining and the number of broker non-votes for each nominee are listed below. The proposal to ratify the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm, the proposal to approve, by non-binding advisory vote, the Company’s executive compensation, and the proposal to amend the Company’s Restated Articles of Organization, as amended, and the Company’s Amended and Restated By-laws to implement the Majority Voting Standard were also approved. The final number of votes cast for or against or abstaining from voting on those three proposals and the number of broker non-votes on the executive compensation proposal and the Majority Voting Standard proposal are listed below. The shareholder proposal regarding ability to call special shareholder meeting was approved. The final number of votes cast for or against or abstaining from voting and the number of broker non-votes on that proposal are listed below.


    Proposal #1 – To elect the following nominees as our directors for terms of one year each:

     

    Name    Votes in Favor      Votes Against      Abstentions      Broker Non-Votes  

    Peter Barrett, PhD

         97,163,257        4,306,671        54,311        4,155,796  

    Samuel R. Chapin

         100,030,553        1,420,897        72,789        4,155,796  

    Michael A. Klobuchar

         101,183,877        280,115        60,247        4,155,796  

    Michelle McMurray-Heath, MD, PhD

         101,281,324        193,378        49,537        4,155,796  

    Alexis P. Michas

         98,367,736        3,103,143        53,360        4,155,796  

    Prahlad R. Singh, PhD

         101,268,785        197,380        58,074        4,155,796  

    Sophie V. Vandebroek, PhD

         101,272,302        198,804        53,133        4,155,796  

    Michael Vounatsos

         98,842,306        2,608,120        73,813        4,155,796  

    Frank Witney, PhD

         100,141,849        1,322,316        60,074        4,155,796  

    Pascale Witz

         101,267,012        197,912        59,315        4,155,796  

    Proposal #2 – To ratify the selection of Deloitte & Touche LLP as the Company’s independent public accounting firm for the current fiscal year.

     

    For   Against   Abstain   Broker Non-Votes
    103,598,283   1,968,762   112,990   0

    Proposal #3 – To approve, by non-binding advisory vote, the Company’s executive compensation.

     

    For   Against   Abstain   Broker Non-Votes
    92,835,062   8,444,564   244,613   4,155,796

    Proposal #4 – To amend the Company’s Restated Articles of Organization, as amended, and the Company’s Amended and Restated By-laws to implement the Majority Voting Standard.

     

    For   Against   Abstain   Broker Non-Votes
    98,409,372   363,712   2,751,155   4,155,796

    Proposal #5- Shareholder proposal regarding ability to call special shareholder meeting.

     

    For   Against   Abstain   Broker Non-Votes
    66,916,220   35,272,422   335,597   4,155,796


    Item 9.01.

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit
    No.

      

    Description

    3.1    Articles of Amendment to Restated Articles of Organization, as amended, effective as of April 23, 2025.
    3.2    Articles of Correction to Restated Articles of Organization, as amended, effective as of April 23, 2025.
    3.3    Amended and Restated By-laws, redlined for amendments effective as of April 24, 2025.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        REVVITY, INC.
    Date: April 25, 2025     By:  

    /s/ John L. Healy

          John L. Healy
          Vice President and Assistant Secretary
    Get the next $RVTY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    7/8/2024$125.00Outperform
    Leerink Partners
    6/3/2024$115.00Hold
    Jefferies
    1/16/2024$105.00 → $125.00Buy → Neutral
    UBS
    More analyst ratings

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity upgraded by UBS with a new price target

    UBS upgraded Revvity from Neutral to Buy and set a new price target of $115.00

    5/1/25 7:42:49 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity downgraded by Bernstein with a new price target

    Bernstein downgraded Revvity from Outperform to Mkt Perform and set a new price target of $130.00

    1/10/25 8:41:17 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity upgraded by BofA Securities with a new price target

    BofA Securities upgraded Revvity from Neutral to Buy and set a new price target of $138.00

    12/13/24 8:43:02 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity Unveils New AI Software Offering to Transform Preclinical Imaging Analysis

    New software further strengthens Revvity's market-leading position in in vivo imaging while empowering scientists with faster, more reproducible insights Today Revvity, Inc. (NYSE: RVTY), announced the launch of its Living Image™ Synergy AI multimodal analysis software for in vivo imaging researchers. The solution provides a unified platform with AI capabilities for seamless data analysis across optical, microCT, ultrasound, and other modalities—reducing data inconsistencies, streamlining workflows, increasing throughput, and enhancing reproducibility, all with the intention of accelerating scientific discovery. "Our Living Image Synergy AI software marks a significant leap forward in p

    9/29/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Lab Automation Market is Projected To Reach US$8.71 Billion By 2031 at CAGR of 6.3% | The Insight Partners

    NEW YORK, Sept. 22, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global lab automation market is observing significant growth due to technological advancements, regulatory & quality compliance, and demand for efficiency & throughput. The report runs an in-depth analysis of market trends, key players, and future opportunities. The lab automation market generally comprises a vast array of types, equipment, applications, end users, and geography, which are expected to register strength in the coming years. Check valuable insights in the Lab Automation Market report. You can easily get a sample PDF of the report - https://www.theinsightpartners.com

    9/22/25 11:30:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity and Profluent Collaborate to Launch AI-Enhanced Adenine Deaminase Pin-point Base Editing Systems

    Combination of Revvity's proprietary Pin-point platform and Profluent's AI-engineered proteins created to inspire accelerated development of novel gene editing therapies Revvity, Inc. (NYSE:RVTY) announced a strategic collaboration with Profluent, bringing together a range of its novel AI-engineered enzymes with Revvity's established Pin-pointTM base editing platform. The result is simplified access for customers to a therapeutically relevant base editing toolkit. This new Pin-point configuration allows for increased precision and efficiency, with some combinations being precise to single nucleotide edits without bystander editing. Additionally, the Pin-point platform's modular design h

    9/22/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Gonzales Anita covered exercise/tax liability with 149 shares, decreasing direct ownership by 3% to 4,340 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    9/17/25 4:05:09 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Krakowiak Maxwell covered exercise/tax liability with 559 shares, decreasing direct ownership by 4% to 12,217 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    9/17/25 4:05:14 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Michas Alexis P sold $44,505 worth of shares (500 units at $89.01) (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    8/28/25 4:05:04 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    SEC Filings

    View All

    SEC Form 10-Q filed by Revvity Inc.

    10-Q - REVVITY, INC. (0000031791) (Filer)

    8/5/25 4:10:32 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - REVVITY, INC. (0000031791) (Filer)

    7/28/25 7:12:47 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 11-K filed by Revvity Inc.

    11-K - REVVITY, INC. (0000031791) (Filer)

    6/20/25 2:18:15 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Establishes In Vivo Imaging Center of Excellence in North Carolina

    Facility designed to advance the next generation of imaging systems Revvity, Inc. (NYSE:RVTY), today announced the opening of its new In Vivo Imaging Center of Excellence in Morrisville, North Carolina, the heart of the state's Research Triangle. The center consolidates Revvity's expertise and resources to drive R&D innovation and create the next generation of imaging systems backed by AI software tools and other advanced technologies. The new facility is staffed by R&D teams from across the organization, including software, hardware, and applied biology/applications teams, as well as those specialized in machine learning, optical, microCT, and ultrasound. Combined, these teams will hel

    9/2/25 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Second Quarter of 2025

    Revenue of $720 million; 4% reported growth; 3% organic growth GAAP EPS of $0.46; Adjusted EPS from continuing operations of $1.18 Updates full year 2025 guidance Revvity, Inc. (NYSE:RVTY), today reported financial results for the second quarter ended June 29, 2025. The Company reported GAAP earnings per share of $0.46, as compared to $0.45 in the same period a year ago. Revenue for the quarter was $720 million, as compared to $692 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $91 million, as compared to $86 million for the same period a year ago. GAAP operating profit margin from continuing operations was 12.6% as a

    7/28/25 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 7, 2025 to all shareholders of record at the close of business on October 17, 2025. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screenin

    7/24/25 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials